TGR-63 / IGC Pharma - LARVOL DELTA

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology (ACCESS Newswire) - "The data demonstrate that TGR-63 extends its therapeutic potential beyond previously reported effects on beta-amyloid (Aβ) pathology by also inhibiting tau protein aggregation, another key hallmark of Alzheimer's....In in vitro assays, TGR-63 was shown to suppress tau fibril formation at micromolar concentrations..."

Preclinical • Alzheimer's Disease

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease (Businesswire) - "IGC Pharma, Inc...today announced encouraging preclinical results in an Alzheimer’s mouse model demonstrating the potential of the Company’s therapeutic candidate, TGR-63, to combat Alzheimer's disease...In a mouse model of Alzheimer's, TGR-63 treatment led to a substantial reduction of amyloid plaque. Compared to untreated mice, TGR-63 treatment reduced plaque deposits by 78% in the cortex, a critical brain region for memory and cognition, and by 85% in the hippocampus, which plays a central role in learning and memory. These findings suggest TGR-63's potential to slow or even reverse the progression of Alzheimer's disease... IGC Pharma expects to begin a Phase 1 trial for TGR-63 in 2025, although there can be no assurance."

New P1 trial • Preclinical • Alzheimer's Disease • CNS Disorders

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model (Businesswire) - "IGC Pharma, Inc...announced the results of preclinical studies investigating its drug candidate TGR-63 as a treatment for Alzheimer's disease. The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval."

Preclinical • Alzheimer's Disease • CNS Disorders

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model (Businesswire) - "The Company is targeting a Phase 1 trial in 2024...IGC Pharma, Inc...announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease. Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models...'We continue progressing IGC-AD1 and TGR-63 enthusiastically and anticipate clinical milestone updates throughout 2024 from our strengthened AD pipeline.'...The mice in the APP/PS1 group that received TGR-63 treatment showed significant improvements in their emotional well-being and anxiety levels compared to the group that didn't receive treatment. A series of tests were used to measure these improvements."

Clinical • New P1 trial • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia

IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award (Businesswire) - "IGC Pharma, Inc...announced that its Advisor, Professor T. Govindaraju the inventor of the investigational Alzheimer’s drug candidate, TGR-63, received the Government of India-instituted National Technology Award (Translational Research) for 'Outstanding Contribution in Commercializing Innovative Indigenous Technologies' from the Minister of State for Science and Technology and Earth Sciences."

Financing • Alzheimer's Disease • CNS Disorders

IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate (Businesswire) - "India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer’s drug development candidate....JNCASR’s research based on Alzheimer’s cell lines, identified one lead NMI molecule, TGR 63, with the potential to reduce beta amyloid (Aβ) plaques. Further, they demonstrated that the molecule reduces cognitive decline in a transgenic mouse model of Alzheimer’s."

Licensing / partnership • Alzheimer's Disease • CNS Disorders